Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — AACR Investor and Analyst Call 2019
8 slides from Autolus Therapeutics's conference presentation, Apr 2, 2019
Slide 1: Autolus AACR Investor and Analyst Call
Autolus AACR Investor and Analyst Call April 2nd, 2019 Exhibit 99.2
Slide 2: Forward-looking statements
These slides and the accompanying oral presentation made by Autolus Therapeutics plc (“Autolus” or the “Company”) contain forward-looking statements within the meaning of the “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including statements about the Company's on
Slide 3: AUTO1 CAR T cell therapy designed to reduce severe CRS risk
AUTO1 CAR T cell therapy designed to reduce the risk of severe CRS and improve the safety profile of the CD19 binder CD19-targeting programmed T cell therapy with a new binder (CAT19) with fast-off kinetics Similar structure to Kymriah®, 41BB endo-domain, lentivial vector Key difference is the binde
Slide 4: AUTO1 and Kymriah: Pediatric ALL
AUTO1 and Kymriah®: Pediatric ALL1 AUTO1 has 0% ≥Grade 3 CRS & may need lower intensity of care AUTO1 - one patient died due to a serious adverse event (sepsis) * All data as of the November 16, 2018 data cut off Kymriah® - eleven patients died, including four due to adverse events (encephalitis, ce
Slide 5: AUTO1 and Kymriah: Pediatric ALL expansion and dose
AUTO1 and Kymriah®: Pediatric ALL AUTO1 Dose 1mil/kg vs 2-5mil/kg Kymriah Peak expansion : 10x higher than Kymriah AUC: 10x of Kymriah We believe AUTO 1 may have lower toxicity We believe the safety profile may enable AUTO1 to be well-suited for the treatment of adult ALL: older patients, more co-mo
Slide 6: Next Steps for AUTO1
Next Steps for AUTO1 April 2nd, 2019
Slide 7: Key Outcomes of CD19 CARs and BiTEs in ALL
Key Outcomes of CD19 CARs and BiTEs in ALL 1Kymriah- pALL 2AUTO1 - pALL 3AUTO1 aALL 4YESCARTA 5Blinatumomab Patient Numbers 75 14 10 14 271 CR Rate 81% 86% 88% 93% 42% EFS EFS 12m: 50% (95% CI, 35 to 64) EFS 12m: 46% (95% CI, 16 to 72) tbd tbd EFS 6m: 30% CRS ≥ Grade 3 47% 0% 0%* 18% 3% Neurotox ≥ G
Slide 8: Outlook and Next Steps
AUTO1 Outlook and Next Steps This initial data set for AUTO1 from the Phase 1/2 ALLCAR19 trial in adult r/r B-ALL patients indicates a potential attractive safety profile Further follow up will provide information on durability of treatment effect Level of CD19-negative relapse rate is too early to
Autolus Therapeutics — AACR Investor and Analyst Call 2019 on 6ix